🏆 Deal of the Week · CW 31/2025
Ultromics raised USD 55 million in a Series C round; the post-money valuation was not disclosed. The round drew participation from nine investors including GV, Lightrock, and Legal & General Investment Management (LGIM), among others.
Ultromics — key deal facts
| Company | Ultromics |
| Founded | 2017 |
| Headquarters | Oxford, United Kingdom |
| Amount raised | USD 55m |
| Valuation | Valuation Remains Undisclosed |
| Round | Series C |
| Investors | Allegis Capital, GV, Legal & General Investment Management (LGIM), Lightrock, Oxford Science Enterprises, The Blue Venture Fund, UCM Ventures, University of Oxford, UPMC Enterprises |
| Sectors | Artificial Intelligence (AI) |
Who invested in Ultromics?
The round was backed by Allegis Capital, GV, Legal & General Investment Management (LGIM), Lightrock, Oxford Science Enterprises, The Blue Venture Fund, UCM Ventures, University of Oxford, and UPMC Enterprises. The syndicate is notable for combining deep-tech venture capital with institutional asset managers, a strategic health system operator (UPMC Enterprises), and the company's founding university — reflecting both commercial and clinical validation at Series C stage.
What does Ultromics do?
Ultromics is an Oxford-based health technology company founded in 2017 as a spin-out from the University of Oxford. The company develops AI-driven cardiovascular diagnostics, with its flagship EchoGo® platform — an FDA-cleared tool that autonomously analyzes routine echocardiograms to detect conditions such as heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis. CEO and Founder Ross Upton, PhD, built the platform on one of the largest known echocardiography datasets in the field, enabling clinicians to make faster and more accurate diagnostic decisions.
Ultromics valuation & multiples
No verified valuation was disclosed for this round, so transaction multiples cannot be calculated from this financing event alone. Comparable AI-driven medical diagnostics companies typically trade in a wide EV/Sales range, reflecting the high growth and pre-profitability nature of the sector. For sector-level benchmarks, visit the Venionaire DealMatrix AI and MedTech multiples pages.
Explore the benchmarks: Series C.
Frequently asked questions
How much did Ultromics raise in its Series C?
Ultromics raised USD 55 million in its Series C round, announced in 2025 (KW 31).
What is Ultromics's valuation?
The post-money valuation of Ultromics was not disclosed in connection with this Series C financing.
Who invested in Ultromics?
The Series C investors include Allegis Capital, GV, Legal & General Investment Management (LGIM), Lightrock, Oxford Science Enterprises, The Blue Venture Fund, UCM Ventures, University of Oxford, and UPMC Enterprises.
When was Ultromics founded and where is it based?
Ultromics was founded in 2017 and is headquartered in Oxford, United Kingdom.
Source: original announcement — read the full report.